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Objectives
Predictive biomarkers can be used to identify most suita-
ble treatments for patients. To maximise patient benefit
valid predictive biomarkers need to be used and several
trial designs have been proposed to achieve this.
We aimed to review the evidence considered sufficient
by the European Medicines Agency (EMA) for inclusion
of a predictive biomarker in a drug indication or contra-
indication and this required development of a methodol-
ogy to summarise key information.
Methods
We reviewed the evidence supporting 49 biomarker-indi-
cation-drug combinations (37 different biomarkers and
41 drugs) within EMA licensing. The main issues consid-
ered were: biomarker evaluation design, sample size,
representativeness of patients in trials, primary outcome
type and strength of findings. We developed a novel
visual overview of these dimensions in radial plots. We
explored whether there were differences in the evidence
base depending on authorisation recommendation, dis-
ease area, biomarker type and orphan designation.
Results
155 studies were identified: one biomarker strategy
design, 45 enrichment studies, 37 RCT subgroup ana-
lyses and 72 other designs (mainly single arm, case ser-
ies and reports). A median of 2 studies (range: none to
19) supported a biomarker-indication-drug combination.
Comparison of evidence depending on factors outlined
above will be reported.
Conclusions
There was a wide variation in type and quantity of evi-
dence supporting biomarker-indication-drug combinations
and the radial plots were a useful means of assessment.
Study designs used were not always robust. It was not
always clear why certain predictive biomarkers were
included in the indication. The role of the biomarker eva-
luation context seemed important.
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